Topics

Sandoz Enters Agreement with EirGenix for Proposed Trastuzumab Biosimilar in Phase 3 Development

11:28 EDT 30 Apr 2019 | Speciality Pharma Journal

Holzkirchen, Germany, April 30, 2018 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This medicine is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer …

Original Article: Sandoz Enters Agreement with EirGenix for Proposed Trastuzumab Biosimilar in Phase 3 Development

NEXT ARTICLE

More From BioPortfolio on "Sandoz Enters Agreement with EirGenix for Proposed Trastuzumab Biosimilar in Phase 3 Development"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...